Drugs / YH42946
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06616766 | Oct 2024 → Mar 2028 expected | non-small cell lung carcinoma | Yuhan Corporation | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YH42946 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06616766 ↗ |
| Action | Inhibit | “tyrosine kinase inhibitor targeting HER2” NCT06616766 ↗ |
| Route | Oral | “orally available” NCT06616766 ↗ |
| Target | ERBB2 | “tyrosine kinase inhibitor targeting HER2” NCT06616766 ↗ |